News Teva Pharmaceuticals to Present New Data on Multiple Sclerosis Drugs Copaxone and Laquinimod at ECTRIMS 2015 Teva Pharmaceuticals to Present New Data on Multiple Sclerosis Drugs Copaxone and Laquinimod at ECTRIMS 2015 by Patricia Silva, PhD | October 7, 2015 Share this article: Share article via email Copy article link The world’sĀ largest generic medicines manufacturer,Ā Teva Pharmaceutical, is at theĀ 31st European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress currently ongoing in Barcelona, from October 7-10, 2015. Teva will be presenting the latest findings on its relapsing multiple sclerosis (MS) therapy COPAXONEĀ®Ā (glatiramer acetate injection), and product candidate for relapsing and progressive MS, laquinimod –Ā a once-daily oral, investigational, central nervous system (CNS)-active immunomodulator with a novel mechanism of action, which is being developed for the treatment of relapsing-remitting MS (RRMS), progressive MS and Huntingtonās disease. āNew COPAXONEĀ®Ā data at this yearās Congress underscore the safety and efficacy of the three-times-a-week treatment, as well as explore the decreased incidence of adverse events for COPAXONEĀ®Ā 40 mg/mL patients, while laquinimod data focus on long-term measures such as disability progression,ā said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva in a press release. āThe data being presented emphasizes our dedication to better understanding the long-term benefit of COPAXONEĀ®Ā and potential for laquinimod.ā Teva’s conference booth, “Hope in the Code” will highlight its commitment to personalized medicine. The company will also be hosting a Satellite Symposium, titled āDiscovering a New World in MS,ā on Thursday, October 8, 2015 beginningĀ 19:15 until 20:15 CEST. According to the press release, the presentations sponsored by Teva include: COPAXONEĀ®Ā (glatiramer acetate injection) Efficacy and safety of a three-times weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the glatiramer acetate low-frequency administration (GALA) open-label extension studyĀ (Poster Session 1, October 8, 2015, 15:45 ā 17:00) O. Khan, P. Rieckmann, S. Kolodny, MD. Davis, N. Ashtamker, JR. Steinerman, R. Zivadinov Disease-modifying therapy improved depression symptoms in multiple sclerosis patients: the POSIDONIA studyĀ (Poster Session 1, October 8, 2015, 15:45 ā 17:00) E. Montanari, M. Conti, D. Maimone, V. Torri Clerici, K. Plewnia, M. Frigo, A. Francia, A. Pala, A. Veneziano Comparison of physicochemical, biological and genomic characteristics of differently manufactured glatiramoids to ensure MS patient safetyĀ (e-Poster Session 1, October 8, 2015, 15:45 ā 17:00) A. Komlosh, T. Hasson, K. Wells-Knecht, T. Molotsky, R. Krispin, G. Papir, D. Pinkert, H. Cooperman, S. Bakshi, S. Kolitz, F. Towfic, B. Weiner, B. Zeskind, D. Laifenfeld, D. Ladkani, V. Weinstein, I. Grossman, M.R. Hayden Statistical comparison of adverse events for glatiramer acetate 20mg vs 40mg for the treatment of relapsing-remitting multiple sclerosisĀ (Poster Session 2, October 9, 2015, 15:30 ā 17:00) F.J. Zagmutt, Y. Wu, A. Grinspan, S. Kolodny, S. Gandhi Evaluating the effect of enhanced physical activity and energy management on fatigue in patients suffering from multiple sclerosis: the MS TeleCoach studyĀ (Poster Session 2, October 9, 2015, 15:45 ā 17:00) M. D’hooghe, G. Van Gassen, D. Kos, B. Van Wijmeersch, B. Willekens, D. Decoo, M. Cambron, I.-K. Penner, P. Vanderdonckt, J. Debruyne, R. Crols, A. Lysandropoulos, S. Elsankari, P. Seeldrayers, A. MĆ©lin, P. Laloux, O. Bouquiaux, R. Reznik, G. Nagels The Glatiramer acetate pregnancy database (Poster Session 2, October 9, 2015, 15:30 ā 1700) O. Neudorfer, M. Sandberg-Wollheim, P.K. Coyle, B. Weinstock-Guttman, A. Perrin Ross, A. Grinspan Glatiramer acetate slows disability progression – results from a 6-year analysis of the UK Risk Sharing SchemeĀ (Poster Session 2, October 9, 2015, 15:30 ā 17:00) G. Giovannoni, P. Brex, M. Sumra, E. Walters, K. Schmierer Laquinimod Long-term follow-up of laquinimod in patients with relapsing-remitting multiple sclerosis (Poster Session 1, October 8, 2015, 15:45 ā 17:00) G. Comi, T.L. Vollmer, F.D. Lublin, Y. Dadon, T. Gorfine, M.D. Davis, P.S. SĆørensen, V. Knappertz Effects of laquinimod on microglia and monocytes following traumatic brain injuryĀ (Poster Session 1, October 8, 2015, 15:45 ā 17:00) A. Katsumoto, A.S. Miranda, O. Butovsky, Z. Fanek, R.M. Ransohoff, B.T. Lamb Effect of laquinimod, a novel immunomodulator in development for treatment of multiple sclerosis, on cardiac repolarization in healthy subjects: a thorough QT/QTc studyĀ (Poster Session 1, October 8, 2015, 15:45 ā 17:00) A. Elgart, D. Mimrod, L. Rabinovich-Guilatt, E. Eyal, J. Morganroth, O. Spiegelstein Disability outcome and sample size considerations for PPMS clinical trial efficiencyĀ (Poster Session 2, October 9, 2015, 15:30 ā 17:00) M.D. Davis, J.R. Steinerman, N. Sasson, V. Knappertz Laquinimod reduces CNS pathology and demyelination induced by B lymphocytes from multiple sclerosis patients in a novel brain slice model of MS (Poster Session 2, October 9, 2015, 15:30 ā 17:00) D.E. Harlow, S. Selva, K.E. Saul, L.J. Jackson, W.B. Macklin, T.L. Vollmer Laquinimod is protective to oligodendrocytes during lysolecithin-induced demyelination in a murine brain slice model (Poster Session 2, October 9, 2015, 15:30 ā 17:00) D.E. Harlow, K.E. Saul, W.B. Macklin, T.L. Vollmer MRI measures and disability progression in PPMS: analysis of the PROMiSe clinical trial dataset(Free Communications 1, October 9, 2015, 9:39 ā 9:51) M.W. Koch, J.R. Steinerman, V. Knappertz, M.D. Davis, G. Giovannoni, G.R. Cutter, J.S. Wolinsky Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags conference, Copaxone, ECTRIMS, Laquinimod, Teva Pharmaceuticals
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS
April 18, 2024 Columns by Benjamin Hofmeister Learning how to write a ‘SOAP’ note feels different after an MS diagnosis
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8